These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23932312)

  • 1. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study.
    Bay-Jensen AC; Platt A; Byrjalsen I; Vergnoud P; Christiansen C; Karsdal MA
    Semin Arthritis Rheum; 2014 Feb; 43(4):470-8. PubMed ID: 23932312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study.
    Bay-Jensen AC; Platt A; Siebuhr AS; Christiansen C; Byrjalsen I; Karsdal MA
    Arthritis Res Ther; 2016 Jan; 18():13. PubMed ID: 26787505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
    Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS
    Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.
    Juhl P; Thudium CS; Gudmann NS; Karsdal MA; Bay-Jensen AC; Siebuhr AS
    Clin Exp Rheumatol; 2018; 36(4):568-574. PubMed ID: 29465346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
    Gudmann NS; Junker P; Juhl P; Thudium CS; Siebuhr AS; Byrjalsen I; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(5):829-835. PubMed ID: 29745884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
    Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
    Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis.
    Maijer KI; Gudmann NS; Karsdal MA; Gerlag DM; Tak PP; Bay-Jensen AC
    PLoS One; 2016; 11(3):e0149329. PubMed ID: 27019199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.
    Gudmann NS; Hirata S; Karsdal MA; Kubo S; Bay-Jensen AC; Tanaka Y
    Clin Exp Rheumatol; 2018; 36(3):462-470. PubMed ID: 29465351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
    Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
    Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.
    Siebuhr AS; Kjelgaard-Petersen CF; Sun S; Byrjalsen I; Christiansen C; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(1):94-101. PubMed ID: 28850021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
    PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis.
    Bay-Jensen AC; Wichuk S; Byrjalsen I; Leeming DJ; Morency N; Christiansen C; Karsdal MA; Maksymowych WP
    PLoS One; 2013; 8(1):e54504. PubMed ID: 23365672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
    Shafran IH; Alasti F; Smolen JS; Aletaha D
    Ann Rheum Dis; 2020 Jul; 79(7):874-882. PubMed ID: 32371387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.